CEL-SCI Corporation Closes $7.2 Million Public Offering to Advance Multikine Development

CEL-SCI Corporation (NYSE American: CVM) announced the closing of its best-efforts public offering of 6 million shares of common stock priced at $1.20 per share, resulting in gross proceeds of approximately $7.2 million before fees and expenses. The company stated that net proceeds will be used to support continued development of Multikine, its investigational immunotherapy for head and neck cancer, as well as for general corporate purposes and working capital. This capital infusion comes at a critical time as CEL-SCI prepares for potential regulatory submissions and further clinical trials.

Multikine (Leukocyte Interleukin, Injection) is designed to be administered shortly after diagnosis but before surgery, radiotherapy, or chemotherapy, aiming to boost the patient's immune system while it is still relatively intact. The therapy has received Orphan Drug designation from the U.S. Food and Drug Administration for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck. To date, Multikine has been dosed in over 740 patients. The company believes that stimulating the immune system prior to standard treatments could provide a greater impact on survival by enabling the immune system to better target the tumor.

The closing of this offering provides CEL-SCI with additional financial runway to advance its clinical programs. According to the press release, the company plans to allocate the net proceeds primarily toward Multikine's development, which includes ongoing and planned clinical studies, manufacturing, and regulatory activities. For more details, the full press release is available at https://ibn.fm/T5Ng2.

Headquartered in Vienna, Virginia, with operations near Baltimore, Maryland, CEL-SCI is focused on researching and developing cancer immunotherapies. The company's approach is based on the premise that treating the immune system before it is compromised by standard cancer treatments could lead to better outcomes. Multikine represents a novel strategy in the fight against head and neck cancer, a disease with significant unmet medical need. Additional information about CEL-SCI can be found on its website at https://cel-sci.com/.

The successful completion of this public offering underscores investor interest in CEL-SCI's pipeline and the potential of Multikine. With the additional capital, the company is better positioned to navigate the regulatory landscape and bring its therapy closer to patients. The implications of this funding are significant for CEL-SCI's stakeholders, as it provides the resources needed to continue pivotal trials and potentially submit for marketing approval. As CEL-SCI progresses, the oncology community will be watching closely to see if Multikine can deliver on its promise to improve survival rates for head and neck cancer patients.